Genetic Technologies has registered a patent infringement lawsuit against Reproductive Genetics Institute in the US District Court for the Northern District of Illinois.

The law suit has been filed for continuing to infringe Genetic’s BREVAGen breast cancer risk stratification test, designed for examining patient’s DNA to detect the absence or presence of certain common genetic variations associated with an increased risk for developing breast cancer.

Based on a patient’s family and personal history, the test helps physicians to assess factors from a standard clinical assessment and recommend alternative courses of action such as more vigilant, targeted surveillance or preventive therapy.

The company believes that the BREVAGen test may be useful for women predisposed to hormone-dependant breast cancer, including those who have undergone breast biopsies.